Incyte Corporation drugs

7 results

  • jakafi

    (ruxolitinib)
    Incyte Corporation
    Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in patients aged 12 and older who have not responded to prior systemic therapies.
    Medication Details
    Drug Interactions

  • niktimvo

    (axatilimab-csfr)
    Incyte Corporation
    NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, following the failure of at least two prior lines of systemic therapy.
    Medication Details
    Drug Interactions

  • opzelura

    (ruxolitinib)
    Incyte Corporation
    OPZELURA is indicated for the topical short-term treatment of mild to moderate atopic dermatitis in patients 12 years and older, and for nonsegmental vitiligo in adults and pediatric patients. It should not be used in combination with other JAK inhibitors or potent immunosuppressants.
    Medication Details
    Drug Interactions

  • pemazyre

    (pemigatinib)
    Incyte Corporation
    PEMAZYRE is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, and for adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
    Medication Details
    Drug Interactions